IRADIMED CORP (IRMD) Fundamental Analysis & Valuation
NASDAQ:IRMD • US46266A1097
Current stock price
84.49 USD
-4.59 (-5.15%)
At close:
84.49 USD
0 (0%)
After Hours:
This IRMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. IRMD Profitability Analysis
1.1 Basic Checks
- In the past year IRMD was profitable.
- In the past year IRMD had a positive cash flow from operations.
- In the past 5 years IRMD has always been profitable.
- Each year in the past 5 years IRMD had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 20.67%, IRMD belongs to the best of the industry, outperforming 98.40% of the companies in the same industry.
- IRMD's Return On Equity of 23.76% is amongst the best of the industry. IRMD outperforms 95.72% of its industry peers.
- IRMD has a better Return On Invested Capital (21.02%) than 98.40% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for IRMD is significantly above the industry average of 9.12%.
- The last Return On Invested Capital (21.02%) for IRMD is above the 3 year average (20.45%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.67% | ||
| ROE | 23.76% | ||
| ROIC | 21.02% |
ROA(3y)19.63%
ROA(5y)17.03%
ROE(3y)23.33%
ROE(5y)20.07%
ROIC(3y)20.45%
ROIC(5y)17.53%
1.3 Margins
- IRMD has a better Profit Margin (26.82%) than 96.79% of its industry peers.
- IRMD's Profit Margin has improved in the last couple of years.
- IRMD has a better Operating Margin (31.20%) than 98.40% of its industry peers.
- In the last couple of years the Operating Margin of IRMD has grown nicely.
- IRMD has a better Gross Margin (76.75%) than 87.17% of its industry peers.
- IRMD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.2% | ||
| PM (TTM) | 26.82% | ||
| GM | 76.75% |
OM growth 3Y2.08%
OM growth 5YN/A
PM growth 3Y3.67%
PM growth 5Y44.08%
GM growth 3Y-0.3%
GM growth 5Y0.65%
2. IRMD Health Analysis
2.1 Basic Checks
- IRMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- The number of shares outstanding for IRMD has been increased compared to 1 year ago.
- The number of shares outstanding for IRMD has been increased compared to 5 years ago.
- There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 51.42 indicates that IRMD is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 51.42, IRMD belongs to the top of the industry, outperforming 98.40% of the companies in the same industry.
- There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 51.42 |
ROIC/WACC2.34
WACC8.99%
2.3 Liquidity
- IRMD has a Current Ratio of 7.98. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
- IRMD's Current ratio of 7.98 is amongst the best of the industry. IRMD outperforms 88.24% of its industry peers.
- IRMD has a Quick Ratio of 6.84. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of IRMD (6.84) is better than 88.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.98 | ||
| Quick Ratio | 6.84 |
3. IRMD Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an nice 16.36% over the past year.
- The Earnings Per Share has been growing by 36.18% on average over the past years. This is a very strong growth
- IRMD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.43%.
- The Revenue has been growing by 21.45% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)16.36%
EPS 3Y20.77%
EPS 5Y36.18%
EPS Q2Q%22.73%
Revenue 1Y (TTM)14.43%
Revenue growth 3Y16.29%
Revenue growth 5Y21.45%
Sales Q2Q%17.03%
3.2 Future
- IRMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.36% yearly.
- IRMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.02% yearly.
EPS Next Y10.5%
EPS Next 2Y11.02%
EPS Next 3Y12.36%
EPS Next 5YN/A
Revenue Next Year11.66%
Revenue Next 2Y11.49%
Revenue Next 3Y13.56%
Revenue Next 5Y12.02%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. IRMD Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 44.01, IRMD can be considered very expensive at the moment.
- IRMD's Price/Earnings ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 66.84% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 26.89, IRMD is valued quite expensively.
- With a Price/Forward Earnings ratio of 39.82, IRMD can be considered very expensive at the moment.
- 68.98% of the companies in the same industry are more expensive than IRMD, based on the Price/Forward Earnings ratio.
- When comparing the Price/Forward Earnings ratio of IRMD to the average of the S&P500 Index (21.97), we can say IRMD is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.01 | ||
| Fwd PE | 39.82 |
4.2 Price Multiples
- IRMD's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 67.38% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 71.12% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 65.34 | ||
| EV/EBITDA | 39.81 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The excellent profitability rating of IRMD may justify a higher PE ratio.
- IRMD's earnings are expected to grow with 12.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.19
PEG (5Y)1.22
EPS Next 2Y11.02%
EPS Next 3Y12.36%
5. IRMD Dividend Analysis
5.1 Amount
- With a yearly dividend of 0.80%, IRMD is not a good candidate for dividend investing.
- Compared to an average industry Dividend Yield of 0.25, IRMD pays a better dividend. On top of this IRMD pays more dividend than 90.91% of the companies listed in the same industry.
- With a Dividend Yield of 0.80, IRMD pays less dividend than the S&P500 average, which is at 1.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.8% |
5.2 History
- IRMD has been paying a dividend for over 5 years, so it has already some track record.
- IRMD has decreased its dividend recently.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
- 66.90% of the earnings are spent on dividend by IRMD. This is not a sustainable payout ratio.
DP66.9%
EPS Next 2Y11.02%
EPS Next 3Y12.36%
IRMD Fundamentals: All Metrics, Ratios and Statistics
84.49
-4.59 (-5.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10 2026-02-10/bmo
Earnings (Next)05-04 2026-05-04
Inst Owners58.92%
Inst Owner Change0.57%
Ins Owners36.61%
Ins Owner Change-0.98%
Market Cap1.08B
Revenue(TTM)83.81M
Net Income(TTM)22.48M
Analysts82.5
Price Target121.04 (43.26%)
Short Float %6.67%
Short Ratio6.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.8% |
Yearly Dividend1.18
Dividend Growth(5Y)N/A
DP66.9%
Div Incr Years1
Div Non Decr Years1
Ex-Date02-23 2026-02-23 (0.2)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.78%
Min EPS beat(2)1.27%
Max EPS beat(2)10.29%
EPS beat(4)4
Avg EPS beat(4)5.61%
Min EPS beat(4)0.43%
Max EPS beat(4)10.44%
EPS beat(8)7
Avg EPS beat(8)6.02%
EPS beat(12)10
Avg EPS beat(12)6.52%
EPS beat(16)14
Avg EPS beat(16)7.03%
Revenue beat(2)2
Avg Revenue beat(2)2.2%
Min Revenue beat(2)1.41%
Max Revenue beat(2)3%
Revenue beat(4)3
Avg Revenue beat(4)0.84%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)3%
Revenue beat(8)4
Avg Revenue beat(8)0.28%
Revenue beat(12)7
Avg Revenue beat(12)0.4%
Revenue beat(16)7
Avg Revenue beat(16)0.02%
PT rev (1m)-1.11%
PT rev (3m)19.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.26%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.52%
Revenue NY rev (1m)0.35%
Revenue NY rev (3m)1.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.01 | ||
| Fwd PE | 39.82 | ||
| P/S | 12.88 | ||
| P/FCF | 65.34 | ||
| P/OCF | 43.28 | ||
| P/B | 11.41 | ||
| P/tB | 11.84 | ||
| EV/EBITDA | 39.81 |
EPS(TTM)1.92
EY2.27%
EPS(NY)2.12
Fwd EY2.51%
FCF(TTM)1.29
FCFY1.53%
OCF(TTM)1.95
OCFY2.31%
SpS6.56
BVpS7.4
TBVpS7.14
PEG (NY)4.19
PEG (5Y)1.22
Graham Number17.8839 (-78.83%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.67% | ||
| ROE | 23.76% | ||
| ROCE | 26.52% | ||
| ROIC | 21.02% | ||
| ROICexc | 43.68% | ||
| ROICexgc | 47.04% | ||
| OM | 31.2% | ||
| PM (TTM) | 26.82% | ||
| GM | 76.75% | ||
| FCFM | 19.72% |
ROA(3y)19.63%
ROA(5y)17.03%
ROE(3y)23.33%
ROE(5y)20.07%
ROIC(3y)20.45%
ROIC(5y)17.53%
ROICexc(3y)50.3%
ROICexc(5y)54.7%
ROICexgc(3y)54.98%
ROICexgc(5y)60.13%
ROCE(3y)25.8%
ROCE(5y)22.12%
ROICexgc growth 3Y-13.69%
ROICexgc growth 5YN/A
ROICexc growth 3Y-12.49%
ROICexc growth 5YN/A
OM growth 3Y2.08%
OM growth 5YN/A
PM growth 3Y3.67%
PM growth 5Y44.08%
GM growth 3Y-0.3%
GM growth 5Y0.65%
F-Score6
Asset Turnover0.77
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 722.21% | ||
| Cap/Sales | 10.05% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.34% | ||
| Profit Quality | 73.51% | ||
| Current Ratio | 7.98 | ||
| Quick Ratio | 6.84 | ||
| Altman-Z | 51.42 |
F-Score6
WACC8.99%
ROIC/WACC2.34
Cap/Depr(3y)948.96%
Cap/Depr(5y)635.99%
Cap/Sales(3y)11.43%
Cap/Sales(5y)7.92%
Profit Quality(3y)64.21%
Profit Quality(5y)73.8%
High Growth Momentum
Growth
EPS 1Y (TTM)16.36%
EPS 3Y20.77%
EPS 5Y36.18%
EPS Q2Q%22.73%
EPS Next Y10.5%
EPS Next 2Y11.02%
EPS Next 3Y12.36%
EPS Next 5YN/A
Revenue 1Y (TTM)14.43%
Revenue growth 3Y16.29%
Revenue growth 5Y21.45%
Sales Q2Q%17.03%
Revenue Next Year11.66%
Revenue Next 2Y11.49%
Revenue Next 3Y13.56%
Revenue Next 5Y12.02%
EBIT growth 1Y19.04%
EBIT growth 3Y18.71%
EBIT growth 5YN/A
EBIT Next Year15.66%
EBIT Next 3Y17.6%
EBIT Next 5Y16.29%
FCF growth 1Y-1.68%
FCF growth 3Y26.52%
FCF growth 5Y26.12%
OCF growth 1Y-2.64%
OCF growth 3Y35.44%
OCF growth 5Y33.79%
IRADIMED CORP / IRMD Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for IRADIMED CORP?
ChartMill assigns a fundamental rating of 8 / 10 to IRMD.
Can you provide the valuation status for IRADIMED CORP?
ChartMill assigns a valuation rating of 4 / 10 to IRADIMED CORP (IRMD). This can be considered as Fairly Valued.
What is the profitability of IRMD stock?
IRADIMED CORP (IRMD) has a profitability rating of 9 / 10.
What is the earnings growth outlook for IRADIMED CORP?
The Earnings per Share (EPS) of IRADIMED CORP (IRMD) is expected to grow by 10.5% in the next year.
How sustainable is the dividend of IRADIMED CORP (IRMD) stock?
The dividend rating of IRADIMED CORP (IRMD) is 3 / 10 and the dividend payout ratio is 66.9%.